- Drugs List
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
No dosage adjustment is necessary (see 'Dosage; Adults' section)
Not recommended for children under 12 years.
Children aged 12 years and over:
Normally one micro-enema is used, however a second micro-enema may be administered, if needed, on the same or following day.
Additional Dosage Information
To be administered rectally.
The protective cap should be removed and the applicator inserted gently into the rectum and the tube squeezed until empty. A small quantity of the gel may be used as a lubricant if required.
Recent rectal or anal bleeding
Abdominal pain of unknown cause
Inflammatory bowel disease
Children under 12 years
Precautions and Warnings
Docusate sodium enema is for short term use only, prolonged use can cause atonic non-functioning colon and hypokalaemia.
Pregnancy (see 'Pregnancy' section)
Pregnancy and Lactation
Briggs concludes that there are no reports located linking the use of docusate sodium with congenital defects.
The manufacturer, however, states that there are no adequate data from the use of docusate enema in pregnant women and recommend that as minimal systemic absorption cannot be ruled out following rectal application, docusate sodium enema should be used with caution.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
It is not known whether docusate is excreted in human breast milk. Animals studies have shown excretion of docusate and its metabolites in breast milk when administered systemically. Docusate administered rectally is not known to be harmful.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Advise patients on the correct manner of use.
Rectal burning and pain
Short lasting diarrhoea
Hepatotoxicity has been reported with oral formulations- especially when used with concurrent laxatives
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: February 2012
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.
British National Formulary, 62nd Edition (2011) Pharmaceutical Press, London.
BNF for Children (2011-2012) Pharmaceutical Press, London.
Summary of Product Characteristics: Norgalax. Norgine Limited. Revised July 2010
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.